Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 383

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial

Open access
Lu, Shun, Zhang, Wei, Wu, Lin, Wang, Wenxiang, Zhang, Peng, Neotorch Investigators, Fang, Wentao, Xing, Wenqun, Chen, Qixun, Yang, Lin, Mei, Jiandong, Tan, Lijie, Sun, Xiaohong, Xu, Shidong, Hu, Xiaohua, Yu, Guohua, Yu, Dongliang, Yang, Nong, Chen, Yuping, Shan, Jinlu, Xing, Ligang, Tian, Hui, Zhang, Xun, Zhou, Ming, Fang, Haohui, Wu, Guowu, Liu, Yunpeng, Ye, Minhua, Cao, Lejie, Jiang, Jie, Li, Xingya, Zhu, Liangming, Li, Shanqing, Kang, Mingqiang, Zhong, Aihong, Chen, Keneng, Wu, Nan, Sun, Qian, Ma, Haitao, Cai, Kaican, Wang, Changli, Lin, Gen, Zhu, Kunshou, Zhang, Yu, Zhang, Xiaochun, Hu, Hong, Zhang, Wengang, Chen, Jun, Yang, Zhixiong, Hang, Xiaosheng, Hu, Jian, Huang, Yunchao, Zhang, Zhiye, Zhang, Lumin, Zhang, Liwei, Liu, Lunxu, Lin, Dongmei, Zhang, Jie, Chen, Gang, Li, Yuan, Zhu, Lei, Wang, Weihua, Yu, Wenbo, Cao, Dezhen, Keegan, Patricia, Yao, Sheng·2024·JAMA

Abstract

Importance: Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non–small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition with chemotherapy remains unknown. Objective: To determine whether toripalimab in combination with platinum-based chemotherapy will improve event-free survival and major pathological response in patients with stage II or III resectable NSCLC compared with chemotherapy alone. Design, Setting, and Participants: This randomized clinical trial enrolled patients with stage II or III resectable NSCLC (without EGFR or ALK alterations for nonsquamous NSCLC) from March 12, 2020, to June 19, 2023, at 50 participating hospitals in China. The data cutoff date for this interim analysis was November 30, 2022. Interventions: Patients were randomized in a 1:1 ratio to receive 240 mg of toripalimab or placebo once every 3 weeks combined with platinum-based chemotherapy for 3 cycles before surgery and 1 cycle after surgery, followed by toripalimab only (240 mg) or placebo once every 3 weeks for up to 13 cycles. Main Outcomes and Measures: The primary outcomes were event-free survival (assessed by the investigators) and the major pathological response rate (assessed by blinded, independent pathological review). The secondary outcomes included the pathological complete response rate (assessed by blinded, independent pathological review) and adverse events. Results: Of the 501 patients randomized, 404 had stage III NSCLC (202 in the toripalimab + chemotherapy group and 202 in the placebo + chemotherapy group) and 97 had stage II NSCLC and were excluded from this interim analysis. The median age was 62 years (IQR, 56-65 years), 92% of patients were male, and the median follow-up was 18.3 months (IQR, 12.7-22.5 months). For the primary outcome of event-free survival, the median length was not estimable (95% CI, 24.4 months-not estimable) in the toripalimab group compared with 15.1 months (95% CI, 10.6-21.9 months) in the placebo group (hazard ratio, 0.40 [95% CI, 0.28-0.57], P < .001). The major pathological response rate (another primary outcome) was 48.5% (95% CI, 41.4%-55.6%) in the toripalimab group compared with 8.4% (95% CI, 5.0%-13.1%) in the placebo group (between-group difference, 40.2% [95% CI, 32.2%-48.1%], P < .001). The pathological complete response rate (secondary outcome) was 24.8% (95% CI, 19.0%-31.3%) in the toripalimab group compared with 1.0% (95% CI, 0.1%-3.5%) in the placebo group (between-group difference, 23.7% [95% CI, 17.6%-29.8%]). The incidence of immune-related adverse events occurred more frequently in the toripalimab group. No unexpected treatment-related toxic effects were identified. The incidence of grade 3 or higher adverse events, fatal adverse events, and adverse events leading to discontinuation of treatment were comparable between the groups. Conclusions and Relevance: The addition of toripalimab to perioperative chemotherapy led to a significant improvement in event-free survival for patients with resectable stage III NSCLC and this treatment strategy had a manageable safety profile. Trial Registration: ClinicalTrials.gov Identifier: NCT04158440

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2023.24735

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 383

Metadata

Authors
Lu, S., Zhang, W., Wu, L., Wang, W., Zhang, P., Neotorch Investigators, Fang, W., Xing, W., Chen, Q., Yang, L., Mei, J., Tan, L., Sun, X., Xu, S., Hu, X., Yu, G., Yu, D., Yang, N., Chen, Y., Shan, J., Xing, L., Tian, H., Zhang, X., Zhou, M., Fang, H., Wu, G., Liu, Y., Ye, M., Cao, L., Jiang, J., Li, X., Zhu, L., Li, S., Kang, M., Zhong, A., Chen, K., Wu, N., Sun, Q., Ma, H., Cai, K., Wang, C., Lin, G., Zhu, K., Zhang, Y., Zhang, X., Hu, H., Zhang, W., Chen, J., Yang, Z., Hang, X., Hu, J., Huang, Y., Zhang, Z., Zhang, L., Zhang, L., Liu, L., Lin, D., Zhang, J., Chen, G., Li, Y., Zhu, L., Wang, W., Yu, W., Cao, D., Keegan, P., & Yao, S.
Venue
JAMA
Published
2024-01-16
Volume
331
Issue
3
Pages
201
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W4390908539
Cited by
383
References
28
FWCI
97.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2023.24735
The paper
Lu, S., Zhang, W., Wu, L., Wang, W., Zhang, P., Neotorch Investigators, Fang, W., Xing, W., Chen, Q., Yang, L., Mei, J., Tan, L., Sun, X., Xu, S., Hu, X., Yu, G., Yu, D., Yang, N., Chen, Y., . . . Yao, S. (2024). Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2023.24735

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.